Navigation path

Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Ingelvac CircoFLEX   
Auth. number : EU/2/07/079
Active substance : Porcine circovirus type 2 ORF2 protein minimum RP1.0 Maximum RP 3.75
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI09 - Immunologicals for suidae
Pharmacological subgroup: QI09A - Pig
Chemical subgroup: QI09AA - Inactivated viral vaccines
Chemical substance: QI09AA07 - porcine circovirus
(See WHO ATCvet Index)
Indication: For active immunisation of pigs from the age of 2 weeks against porcine circovirus type 2 (PCV2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with PCV2 related disease (PCVD).
In addition, vaccination has been shown to reduce PCV2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.
Onset of protection: 2 weeks post vaccination
Duration of protection: at least 17 weeks.
Marketing Authorisation Holder: Boehringer Ingelheim Vetmedica GmbH
D-55216 Ingelheim am Rhein, Deutschland
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/02/2008 Centralised - Authorisation EMEA/V/C/126 (2008)683 of 13/02/2008
29/04/2009 Centralised - Variation (no change in Commission Decision) EMEA/V/C/126/II/1
04/07/2010 Centralised - Variation EMEA/V/C/126/II/2 (2010)4660 of 01/07/2010
13/07/2010 Centralised - Variation EMEA/V/C/126/IB/3
Updated with Decision(2011)562 of 27/01/2011
03/08/2010 Centralised - Variation (no change in Commission Decision) EMEA/V/C/126/IA/4
01/02/2011 Centralised - Variation (2011)562 of 27/01/2011
29/11/2011 Centralised - Variation EMEA/V/C/126/IB/6/G
Updated with Decision(2011)8845 of 24/11/2011
29/11/2011 Centralised - Variation (2011)8845 of 24/11/2011
17/07/2012 Centralised - Variation EMEA/V/C/126/WS/243 (2012)5015 of 12/07/2012
16/01/2013 Centralised - Renewal EMEA/V/C/126/R/13 (2013)129 of 14/01/2013
06/11/2013 Centralised - Variation EMEA/V/C/126/IAIN/15
Updated with Decision(2014)7148 of 30/09/2014
29/08/2014 Centralised - Variation EMEA/V/C/126/IB/18/G
Updated with Decision(2014)7148 of 30/09/2014
02/10/2014 Centralised - Yearly update (2014)7148 of 30/09/2014
09/07/2015 Centralised - Variation EMEA/V/C/126/II/19
Updated with Decision(2016)5074 of 29/07/2016
20/10/2015 Centralised - Variation EMEA/V/C/126/IAIN/22
Updated with Decision(2016)5074 of 29/07/2016
02/08/2016 Centralised - Yearly update (2016)5074 of 29/07/2016
27/09/2016 Centralised - Variation EMEA/V/C/126/IG/722/24
Updated with Decision(2017)7264 of 24/10/2017
01/09/2017 Centralised - Variation EMEA/V/C/126/IG/831/26
Updated with Decision(2017)7264 of 24/10/2017
26/10/2017 Centralised - Yearly update (2017)7264 of 24/10/2017
24/11/2017 Centralised - Variation EMEA/V/C/126/IG/855/28/G